Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
Scientists have declared the human genome completely decoded. But a look back at the beginnings of their quest reveals how far we still have to go.
Genomics will make possible the kind of customization that undermines the drug industry’s blockbuster mentality. But can Big Pharma kick the habit?
Drug companies make millions on lifestyle potions. Is R&D on more vital therapies lagging?
Bob Swanson, the founder of Genentech, embodied virtues that today’s venture capitalists are badly in need of.
An experimental gene-therapy treatment kills an eighteen-year-old volunteer in a clinical trial. Is this the final blow for a much-beleaguered technology?
The tale of Centocor is the latest reminder that the road to biotech success is seldom straight. Despite the best business plans, something keeps getting in the way. It’s called biology.
Public rejection of “cloned” beef may seem like a knee-jerk reaction to a loaded work. But biotech has a problem that isn’t going away.
Something is seriously amiss when “experts” identifying the century’s greatest journalism overlook coverage of science and technology.
Embryonic stem cells could someday work like micoscopic fountains of youth. Then again, what’s so great about immortality?
A new vaccine will guard American children agains rotavirus. But much of the world will be unable to afford the protection. What to do?